ArticleScientific reports2025
Polyneuropathy in hereditary and wildtype transthyretin amyloidosis, comparison of key clinical features and red flags.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Longitudinal multimodal assessment of peripheral nerve involvement in wild-type transthyretin amyloidosis.Journal of neurology · 2026Article
- Disease modifying treatment of hereditary transthyretin amyloidosis with polyneuropathy in Germany - expert consensus of the German society of amyloid diseases (DGAK) and the German neurological society (DGN).Neurological research and practice · 2026Review
- Real-World Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A Pharmacovigilance Study.Journal of cardiovascular development and disease · 2026Article
- Application of Omics Analysis in the Clinical Practice and Research of Transthyretin Amyloidosis.Genes · 2026Review
- Hereditary Polyneuropathies in the Era of Precision Medicine: Genetic Complexity and Emerging Strategies.Genes · 2026Review
- Targeting transthyretin deposition in lumbar spinal stenosis: a mechanistic rationale for tafamidis.Frontiers in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transthyretin (TTR) amyloidosis manifests in two distinct forms: hereditary (ATTRv) and wild-type transthyretin amyloidosis (ATTRwt). Despite being one of the commonest manifestations in ATTRv amyloidosis, the presence of polyneuropathy has long been underestimated in ATTRwt patients. This prospective study enrolled 72 patients with ATTRv (n = 11) and ATTRwt (n = 61) amyloidosis. Our standardized protocol included a detailed patient history, clinical and electrophysiological examinations, assessment of unrelated neuropathy risk factors and predefined red flags for ATTRv amyloidosis, as well as serum neurofilament light chain concentrations (NfL). We found signs of polyneuropathy in all ATTRv patients and a vast majority of ATTRwt patients (84%). Predefined red flag symptom clusters were prevalent in both subgroups, indicating significant overlap, however gastrointestinal symptoms were more frequent in ATTRv amyloidosis (p = 0.008), while carpal tunnel syndrome was less common (p = 0.015) compared to ATTRwt amyloidosis. The groups differed in severity of polyneuropathy, with ATTRv patients demonstrating more pronounced subjective limitations, greater clinical disability, marked nerve conduction abnormalities, and higher serum NfL concentrations (p = 0.011). Our findings underscore a high prevalence of polyneuropathy in patients with transthyretin amyloidosis, irrespective of its origin. Differences in the severity of polyneuropathy as well as in red flags indicate different underlying mechanisms of damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.